Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index; 16 of the 20 sources its claims cite were checked for support.

Engineering circular RNA for potent and stable translation in eukaryotic cells

Open access

Abstract

Messenger RNA (mRNA) has broad potential for application in biological systems. However, one fundamental limitation to its use is its relatively short half-life in biological systems. Here we develop exogenous circular RNA (circRNA) to extend the duration of protein expression from full-length RNA messages. First, we engineer a self-splicing intron to efficiently circularize a wide range of RNAs up to 5 kb in length in vitro by rationally designing ubiquitous accessory sequences that aid in splicing. We maximize translation of functional protein from these circRNAs in eukaryotic cells, and we find that engineered circRNA purified by high performance liquid chromatography displays exceptional protein production qualities in terms of both quantity of protein produced and stability of production. This study pioneers the use of exogenous circRNA for robust and stable protein expression in eukaryotic cells and demonstrates that circRNA is a promising alternative to linear mRNA.

Overview

CoChat Summary

## TL;DR

The paper engineers exogenous circular RNA (circRNA) systems that can circularize long RNAs up to 5 kb and drive robust protein expression in eukaryotic cells. Compared with linear mRNA, optimized circRNA showed longer-lasting protein production and, after HPLC purification, stronger protein output in the tested cell lines.

## Key findings

  • Adding homology arms to the permuted intron-exon construct increased splicing efficiency from 0% to 16% with weak arms and to 48% with strong arms.
  • Rationally designed spacer sequences improved splicing efficiency from 46% to 87%, and a disruptive spacer completely abrogated splicing.
  • Using the engineered Anabaena catalytic intron increased splicing efficiency from 84% to 95% and reduced circRNA nicking by 37% relative to the T4 catalytic intron.
  • In HEK293 cells, HPLC-purified circRNA produced 811.2% more protein than unmodified linear mRNA at 24 h and 54.5% more than modified linear mRNA; protein-production half-life was 80 h for circRNA versus approximately 43 h and 45 h for the unmodified and modified linear mRNAs, respectively.
  • In HeLa cells, circRNA protein-production half-life was 116 h, compared with approximately 44 h and 49 h for the unmodified and modified linear mRNAs.
  • The CVB3 IRES was 1.5-fold more effective than the EMCV IRES in HEK293 cells and remained superior across HeLa, A549, and Min6 cells tested.

## Methods

  • Engineered circRNAs were built using permuted group I intron/PIE designs with homology arms, spacer sequences, and different IRES elements; constructs included coding regions for GLuc, Firefly luciferase, EGFP, human erythropoietin, and Cas9.
  • RNAs were synthesized by in vitro transcription, circularized with GTP/Mg2+-dependent self-splicing, enriched with RNase R, and purified by gel extraction or size-exclusion HPLC; circularization was assessed by gel analysis, RNase H nicking analysis, and splice-junction sequencing.
  • Functional testing used transfection into HEK293, HeLa, A549, HEK293-GFP, and Min6 cells, with readouts including luminescence, fluorescence, ELISA, flow cytometry, cytokine assays, and qPCR; statistics were by two-tailed unpaired Welch’s t-test.

## Limitations

  • The paper states that longer circRNAs were more prone to nicking during production, which reduced yields and purity.
  • The discussion says more work is needed to optimize translation from circRNA and to study translation efficiency and stability in other cell types and tissues.
  • The paper notes that additional analysis of exogenous circRNA immunogenicity is required, and that suitable delivery vehicles in vitro and in vivo need thorough investigation.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41467-018-05096-6

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Permuted intron-exon splicing and addition of homology arms. a Schematic diagram showing permuted intron-exon construct design and mechanism of splicing. The group I catalytic intron of the T4 phage Td gene is bisected in such a way to preserve structural elements critical for ribozyme folding. Exon fragment 2 is then ligated upstream of exon fragment 1, and a coding region roughly 1.1 kb in length is inserted between the exon-exon junction. During splicing, the 3′ hydroxyl group of a guanosine nucleotide engages in a transesterification reaction at the 5′ splice site. The 5′ intron half is excised, and the freed hydroxyl group at the end of the intermediate engages in a second transesterification at the 3′ splice site, resulting in circularization of the intervening region and excision of the 3′ intron. b RNAFold predictions of precursor RNA secondary structure for homology arm design. Colors denote base pairing probability, with red indicating higher probability. Without homology arms, no base pairing is predicted to occur between the ends of the precursor molecule. c Agarose gel demonstrating the effect of homology arms on splicing. Putative circRNA runs at a higher molecular weight than heavier precursor RNA, as indicated. (−): no homology arms. Weak: weak homology arms, 9 nt. Strong: strong homology arms, 19 nt. d Agarose gel confirmation of precursor RNA circularization. C: precursor RNA (with strong homology arms) subjected to circularization conditions. C + R: Lane C, digested with RNase R. C + R + H: Lane C + R, digested with oligonucleotide-guided RNase H. U: precursor RNA not subjected to circularization conditions. U + H: Lane U, digested with oligonucleotide-guided RNase H. e Sanger sequencing output of RT-PCR across the splice junction of the sample depicted in lane C + R from (d)
Fig. 1 Permuted intron-exon splicing and addition of homology arms. a Schematic diagram showing permuted intron-exon construct design and mechanism of splicing. The group I catalytic intron of the T4 phage Td gene is bisected in such a way to preserve structural elements critical for ribozyme folding. Exon fragment 2 is then ligated upstream of exon fragment 1, and a coding region roughly 1.1 kb in length is inserted between the exon-exon junction. During splicing, the 3′ hydroxyl group of a guanosine nucleotide engages in a transesterification reaction at the 5′ splice site. The 5′ intron half is excised, and the freed hydroxyl group at the end of the intermediate engages in a second transesterification at the 3′ splice site, resulting in circularization of the intervening region and excision of the 3′ intron. b RNAFold predictions of precursor RNA secondary structure for homology arm design. Colors denote base pairing probability, with red indicating higher probability. Without homology arms, no base pairing is predicted to occur between the ends of the precursor molecule. c Agarose gel demonstrating the effect of homology arms on splicing. Putative circRNA runs at a higher molecular weight than heavier precursor RNA, as indicated. (−): no homology arms. Weak: weak homology arms, 9 nt. Strong: strong homology arms, 19 nt. d Agarose gel confirmation of precursor RNA circularization. C: precursor RNA (with strong homology arms) subjected to circularization conditions. C + R: Lane C, digested with RNase R. C + R + H: Lane C + R, digested with oligonucleotide-guided RNase H. U: precursor RNA not subjected to circularization conditions. U + H: Lane U, digested with oligonucleotide-guided RNase H. e Sanger sequencing output of RT-PCR across the splice junction of the sample depicted in lane C + R from (d)CC BY · PubMed Central
Fig. 2 Spacer design and splicing using the Anabaena autocatalytic intron. a RNAFold predictions of precursor RNA secondary structure in the context of designed spacers. Secondary structures potentially important for ribozyme function are identified by black arrows. b Agarose gel demonstrating the effect of spacers on splicing. (−): no spacer. D: disruptive spacer. P1: permissive spacer 1. P2: permissive spacer 2. c RNAFold predictions of precursor RNA secondary structure for internal homology region design. Lack of significant internal homology (Anabaena 1.0) and introduced internal homology (Anabaena 2.0) indicated by black arrows. Splicing bubble indicated as the region between homology arms and internal homology regions that contains the splicing ribozyme. d Agarose gel demonstrating the effect of internal homology on splicing. e Agarose gel comparing the optimized T4 phage splicing reaction to the optimized Anabaena splicing reaction. Anabaena intron halves are of roughly equal lengths, and are less likely to remain associated after splicing in comparison to the T4 phage intron halves despite stronger homology arms
Fig. 2 Spacer design and splicing using the Anabaena autocatalytic intron. a RNAFold predictions of precursor RNA secondary structure in the context of designed spacers. Secondary structures potentially important for ribozyme function are identified by black arrows. b Agarose gel demonstrating the effect of spacers on splicing. (−): no spacer. D: disruptive spacer. P1: permissive spacer 1. P2: permissive spacer 2. c RNAFold predictions of precursor RNA secondary structure for internal homology region design. Lack of significant internal homology (Anabaena 1.0) and introduced internal homology (Anabaena 2.0) indicated by black arrows. Splicing bubble indicated as the region between homology arms and internal homology regions that contains the splicing ribozyme. d Agarose gel demonstrating the effect of internal homology on splicing. e Agarose gel comparing the optimized T4 phage splicing reaction to the optimized Anabaena splicing reaction. Anabaena intron halves are of roughly equal lengths, and are less likely to remain associated after splicing in comparison to the T4 phage intron halves despite stronger homology armsCC BY · PubMed Central
Fig. 3 Evaluation of circularization efficacy and translation for a range of protein-coding circRNAs generated from de-novo engineered precursor RNA. a Schematic diagram showing elements of the engineered self-splicing precursor RNA design. b Agarose gel of precursor RNA containing an EMCV IRES and a variable insert including Gaussia luciferase (GLuc), human erythropoietin (hEpo), EGFP, Firefly luciferase (FLuc), or Cas9 coding regions after circularization and recircularization (R−). CircRNA was enriched by RNase R degradation (R+). c Approximate circRNA yields from treatment of 20 µg of splicing reaction with RNase R, as assessed by spectrophotometry (n = 3). d Luminescence in the supernatant of HEK293 cells 24 h after transfection with circRNA coding for GLuc (n = 4). e Expression of human erythropoietin in the supernatant of HEK293 cells 24 h after transfection with circRNA coding for hEpo as assessed by solid-phase sandwich ELISA (n = 4). f Luminescence in the lysate of HEK293 cells 24 h after transfection with circRNA coding for FLuc (n = 4). g GFP fluorescence in HEK293 cells 24 h after transfection with circRNA coding for EGFP (scale bar: 400 µm). h FACS analysis demonstrating GFP ablation in HEK293-EF1a-GFP cells 4 days after transfection with sgGFP alone (circCas9−) or co-transfected with circRNA coding for Cas9 (circCas9+), indicated by the appearance of a GFP-negative cell population (all data presented as mean + SD, *p < 0.05 (Welch’s t-test))
Fig. 3 Evaluation of circularization efficacy and translation for a range of protein-coding circRNAs generated from de-novo engineered precursor RNA. a Schematic diagram showing elements of the engineered self-splicing precursor RNA design. b Agarose gel of precursor RNA containing an EMCV IRES and a variable insert including Gaussia luciferase (GLuc), human erythropoietin (hEpo), EGFP, Firefly luciferase (FLuc), or Cas9 coding regions after circularization and recircularization (R−). CircRNA was enriched by RNase R degradation (R+). c Approximate circRNA yields from treatment of 20 µg of splicing reaction with RNase R, as assessed by spectrophotometry (n = 3). d Luminescence in the supernatant of HEK293 cells 24 h after transfection with circRNA coding for GLuc (n = 4). e Expression of human erythropoietin in the supernatant of HEK293 cells 24 h after transfection with circRNA coding for hEpo as assessed by solid-phase sandwich ELISA (n = 4). f Luminescence in the lysate of HEK293 cells 24 h after transfection with circRNA coding for FLuc (n = 4). g GFP fluorescence in HEK293 cells 24 h after transfection with circRNA coding for EGFP (scale bar: 400 µm). h FACS analysis demonstrating GFP ablation in HEK293-EF1a-GFP cells 4 days after transfection with sgGFP alone (circCas9−) or co-transfected with circRNA coding for Cas9 (circCas9+), indicated by the appearance of a GFP-negative cell population (all data presented as mean + SD, *p < 0.05 (Welch’s t-test))CC BY · PubMed Central
Fig. 4 IRES efficacy in varying cell and sequence contexts. a Luminescence in the supernatant of HEK293 cells 24 h after transfection with circRNA containing a panel of viral 5′ UTR IRES sequences in GLuc (left axis, dark purple with black outline) and FLuc (right axis, light purple with gray outline) contexts. b Luminescence in the supernatant of HEK293 cells 24 h after transfection with circRNA containing an added polyA(30) or polyAC(30) spacer sequence separating the IRES from the splice junction. (−): no spacer. pAC: 30nt spacer consisting of adenosines and cytosines. pA: 30nt spacer consisting of adenosines. c Luminescence in the supernatant of HEK293 (left axis, dark purple with black outline) and HeLa (right axis, light purple with gray outline) cells 24 h after transfection with the most effective circRNAs by IRES in (b). d Luminescence in the supernatant of A549 (left axis, dark purple with black outline) and Min6 (right axis, light purple with gray outline) cells 24 h after transfection with the most effective circRNAs by IRES in (b) (all data presented as mean + SD, n = 4, *p < 0.05 (Welch’s t-test))
Fig. 4 IRES efficacy in varying cell and sequence contexts. a Luminescence in the supernatant of HEK293 cells 24 h after transfection with circRNA containing a panel of viral 5′ UTR IRES sequences in GLuc (left axis, dark purple with black outline) and FLuc (right axis, light purple with gray outline) contexts. b Luminescence in the supernatant of HEK293 cells 24 h after transfection with circRNA containing an added polyA(30) or polyAC(30) spacer sequence separating the IRES from the splice junction. (−): no spacer. pAC: 30nt spacer consisting of adenosines and cytosines. pA: 30nt spacer consisting of adenosines. c Luminescence in the supernatant of HEK293 (left axis, dark purple with black outline) and HeLa (right axis, light purple with gray outline) cells 24 h after transfection with the most effective circRNAs by IRES in (b). d Luminescence in the supernatant of A549 (left axis, dark purple with black outline) and Min6 (right axis, light purple with gray outline) cells 24 h after transfection with the most effective circRNAs by IRES in (b) (all data presented as mean + SD, n = 4, *p < 0.05 (Welch’s t-test))CC BY · PubMed Central
Fig. 5 HPLC purification of circRNA from splicing reactions. a HPLC chromatogram of linear GLuc RNA (top) and a CVB3-GLuc-pAC splicing reaction (middle). Agarose gel of collected fractions (bottom). b Agarose gel of CVB3-GLuc-pAC purified by different methods. C: splicing reaction. +R: splicing reaction treated with RNase R. +G,R: splicing reaction gel extracted, and then treated with RNase R. +H,R: splicing reaction HPLC purified, and then treated with RNase R. c Luminescence in the supernatant of HEK293 cells 24 h after transfection with the CVB3-GLuc-pAC splicing reactions purified by different methods as noted in (b) (data presented as mean + SD, n = 4, *p < 0.05 (Welch’s t-test))
Fig. 5 HPLC purification of circRNA from splicing reactions. a HPLC chromatogram of linear GLuc RNA (top) and a CVB3-GLuc-pAC splicing reaction (middle). Agarose gel of collected fractions (bottom). b Agarose gel of CVB3-GLuc-pAC purified by different methods. C: splicing reaction. +R: splicing reaction treated with RNase R. +G,R: splicing reaction gel extracted, and then treated with RNase R. +H,R: splicing reaction HPLC purified, and then treated with RNase R. c Luminescence in the supernatant of HEK293 cells 24 h after transfection with the CVB3-GLuc-pAC splicing reactions purified by different methods as noted in (b) (data presented as mean + SD, n = 4, *p < 0.05 (Welch’s t-test))CC BY · PubMed Central
Fig. 6 Translation efficacy of circRNA compared to linear mRNA. a Luminescence in the supernatant of HEK293 (left, black outline) and HeLa (right, gray outline) cells 24 h after transfection with CVB3-GLuc-pAC circRNA or modified or unmodified linear GLuc mRNA (n = 4 HEK293, n = 3 HeLa). b Luminescence in the supernatant of HEK293 cells starting 24 h after transfection with CVB3-GLuc-pAC circRNA or modified or unmodified linear GLuc mRNA and continuing for 6 days (n = 4). c Relative cumulative luminescence produced over 6 days by HEK293 (left, black outline) and HeLa (right, gray outline) cells transfected with CVB3-GLuc-pAC circRNA or modified or unmodified linear GLuc mRNA (n = 4 HEK293, n = 3 HeLa). d Luminescence in the supernatant of HeLa cells starting 24 h after transfection with CVB3-GLuc-pAC circRNA or modified or unmodified linear GLuc mRNA and continuing for 6 days (n = 3). (all data presented as mean + SD, *p < 0.05 (Welch’s t-test))
Fig. 6 Translation efficacy of circRNA compared to linear mRNA. a Luminescence in the supernatant of HEK293 (left, black outline) and HeLa (right, gray outline) cells 24 h after transfection with CVB3-GLuc-pAC circRNA or modified or unmodified linear GLuc mRNA (n = 4 HEK293, n = 3 HeLa). b Luminescence in the supernatant of HEK293 cells starting 24 h after transfection with CVB3-GLuc-pAC circRNA or modified or unmodified linear GLuc mRNA and continuing for 6 days (n = 4). c Relative cumulative luminescence produced over 6 days by HEK293 (left, black outline) and HeLa (right, gray outline) cells transfected with CVB3-GLuc-pAC circRNA or modified or unmodified linear GLuc mRNA (n = 4 HEK293, n = 3 HeLa). d Luminescence in the supernatant of HeLa cells starting 24 h after transfection with CVB3-GLuc-pAC circRNA or modified or unmodified linear GLuc mRNA and continuing for 6 days (n = 3). (all data presented as mean + SD, *p < 0.05 (Welch’s t-test))CC BY · PubMed Central

Verification

Claims the paper makes

9 Valid · 1 Not valid · 3 Not checked · 54 Own results and interpretations

34 more claims

Create a free account to see all 67 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 25
  • Probably not a substantial claim. 9
  • The quote only partly states this claim. 2

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

6 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 28 references

Cited by

See all 853

Metadata

Authors
Wesselhoeft, R. A., Kowalski, P. S., & Anderson, D. G.
Affiliations
  • Koch Institute for Integrative Cancer Research At MIT (US)
  • Massachusetts Institute of Technology (US)
  • Harvard University (US)
Corresponding author
Anderson, Daniel G.
Venue
Nature Communications
Published
2018-07-06
Volume
9
Issue
1
Pages
2629-2629
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2811482166
Cited by
853
References
28
Citations by year
2026: 153 · 2025: 159 · 2024: 148 · 2023: 124 · 2022: 90 · 2021: 83 · 2020: 53 · 2019: 35 · 2018: 7
FWCI
13.89
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc)
  • Nature
Funders
  • DOD | Defense Advanced Research Projects Agency (W32P4Q-13-1-0011)
  • Juvenile Diabetes Research Foundation (3-PDF-2017-383-A-N)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Circular RNAs in diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
Keywords
circular RNA, self-splicing introns, mRNA stability, protein expression, eukaryotic translation, exogenous RNA
MeSH terms
Internal Ribosome Entry Sites, RNA, Circular, Base Sequence, Catalysis, Cell Line, Chromatography, High Pressure Liquid, Eukaryotic Cells, Exons, Genetic Engineering, Humans, Introns, RNA, RNA Splicing, RNA, Messenger, Sequence Homology, Nucleic Acid, Protein Biosynthesis, Open Reading Frames, Anabaena

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Engineering circular RNA for potent and stable translation in eukaryotic cells. https://app.cochat.ai/papers/10.1038/s41467-018-05096-6
The paper
Wesselhoeft, R. A., Kowalski, P. S., & Anderson, D. G. (2018). Engineering circular RNA for potent and stable translation in eukaryotic cells. Nature Communications. https://doi.org/10.1038/s41467-018-05096-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.